NASDAQ: IMMX
IMMIX Biopharma Inc Stock Forecast, Predictions & Price Target

Analyst price target for IMMX

Based on 1 analyst offering 12 month price targets for IMMIX Biopharma Inc

Min Forecast
$7.00+278.38%
Avg Forecast
$7.00+278.38%
Max Forecast
$7.00+278.38%

Should I buy or sell IMMX stock?

Based on 1 analyst offering ratings for IMMIX Biopharma Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IMMX stock forecasts and price targets.

IMMX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-02-10

1 of 1

Forecast return on equity

Is IMMX forecast to generate an efficient return?

Company
N/A
Industry
155.92%
Market
88.69%

Forecast return on assets

Is IMMX forecast to generate an efficient return on assets?

Company
N/A
Industry
32.62%

IMMX earnings per share forecast

What is IMMX's earnings per share in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.85

IMMX revenue forecast

What is IMMX's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$6.0M

IMMX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMMX$1.85$7.00+278.38%Buy
ONCY$0.64$4.33+582.36%Strong Buy
KRON$0.85$1.00+17.23%Hold
PDSB$1.32$14.00+960.61%Strong Buy
PEPG$1.51$10.33+584.30%Hold

IMMIX Biopharma Stock Forecast FAQ

Is IMMIX Biopharma Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: IMMX) stock is to Buy IMMX stock.

Out of 1 analyst, 0 (0%) are recommending IMMX as a Strong Buy, 1 (100%) are recommending IMMX as a Buy, 0 (0%) are recommending IMMX as a Hold, 0 (0%) are recommending IMMX as a Sell, and 0 (0%) are recommending IMMX as a Strong Sell.

If you're new to stock investing, here's how to buy IMMIX Biopharma stock.

What is IMMX's earnings growth forecast for 2025-2025?

(NASDAQ: IMMX) IMMIX Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.06%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.89%.

IMMIX Biopharma's earnings in 2025 is -$21,613,376.

In 2025, IMMX is forecast to generate -$23,563,792 in earnings, with the lowest earnings forecast at -$23,563,792 and the highest earnings forecast at -$23,563,792.

What is IMMX's revenue growth forecast for 2025-2025?

(NASDAQ: IMMX) IMMIX Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.86%.

IMMIX Biopharma's revenue in 2025 is $0.

In 2025, IMMX is forecast to generate $166,332,648 in revenue, with the lowest revenue forecast at $166,332,648 and the highest revenue forecast at $166,332,648.

What is IMMX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: IMMX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 32.62%.

What is IMMX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year IMMX price target, the average IMMX price target is $7.00, with the highest IMMX stock price forecast at $7.00 and the lowest IMMX stock price forecast at $7.00.

The Wall Street analyst predicted that IMMIX Biopharma's share price could reach $7.00 by Feb 10, 2026. The average IMMIX Biopharma stock price prediction forecasts a potential upside of 278.38% from the current IMMX share price of $1.85.

What is IMMX's Earnings Per Share (EPS) forecast for 2025-2025?

(NASDAQ: IMMX) IMMIX Biopharma's current Earnings Per Share (EPS) is -$0.76. In 2025, IMMX's EPS is forecast to hit -$0.85 (min: -$0.85, max: -$0.85).

What is IMMX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: IMMX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.